Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers

Eleonora Rofi, Marzia Del Re, Elena Arrigoni, Mimma Rizzo, Lorenzo Fontanelli, Stefania Crucitta, Giulia Gianfilippo, Giuliana Restante, Stefano Fogli, Camillo Porta, Romano Danesi, Manuela Schmidinger

Research output: Contribution to journalReview article

Abstract

Chemotherapy is the reference treatment for patients with advanced urothelial carcinoma, both in the neo-adjuvant and adjuvant settings; however, the overall outcome remains poor in this patient population. In the last few years, the addition of immune checkpoint inhibitors into the therapeutic armamentarium has changed the therapeutic landscape of several tumor types, including urothelial carcinoma. Many different molecules have been introduced on the market and several questions about immunotherapies are currently open and deserve a critical analysis. The current review article is aimed at describing the clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial malignancies to underline possible pharmacodynamic and pharmacokinetic differences among them.

Original languageEnglish
Pages (from-to)102812
JournalCritical Reviews in Oncology/Hematology
Volume144
DOIs
Publication statusPublished - Dec 2019

    Fingerprint

Cite this

Rofi, E., Del Re, M., Arrigoni, E., Rizzo, M., Fontanelli, L., Crucitta, S., Gianfilippo, G., Restante, G., Fogli, S., Porta, C., Danesi, R., & Schmidinger, M. (2019). Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. Critical Reviews in Oncology/Hematology, 144, 102812. https://doi.org/10.1016/j.critrevonc.2019.09.004